Medical Insurance Fund Regulation Pressures Pharmacy Stocks; ADC and Weight Loss Drug Clinical Progress Draw Attention

Overview

This report is the Morgan Stanley China Healthcare Industry Weekly Report dated May 22, 2026. The report indicates that market sentiment remains weak across all sub-sectors covered this week, with the China healthcare sector falling 3.7% overall, underperforming the Hang Seng Index (-1.4%). Year-to-date, the sector has cumulatively fallen 6.9%, while CDMOs (+9.3%) and Biotech (+7.5%) performed relatively well. The report highlights upcoming ASCO conference-related summary data and points out significant pullbacks in the pharmacy sector due to regulatory pressure. Additionally, the report tracks clinical progress of multiple blockbuster drugs (such as ADC, GLP-1) and consolidation dynamics in the CRO industry.

Core views

Market Performance & Sentiment: This week the China healthcare sector faced pressure overall, with total market cap dropping from $536.1 billion to $516.4 billion. In sub-sectors, the pharmacy sector had the largest decline (-7.8%), mainly due to negative impact from intensified reviews on chain pharmacies abusing medical insurance funds. Digital Health (-9.8%) and Service Class (-12.3%) also saw significant retracement. In contrast, CDMOs (-0.2%) and API (-2.1%) showed some defensiveness. Year-to-date, CDMOs and Biotech were the only sub-sectors achieving positive growth. Key Clinical Progress: In innovative drugs, Duality Biotherapeutics and BioNTech co-developed B7H3 ADC drug (DB1311/BNT324) completed first patient dosing in global Phase III clinical trials for metastatic castration-resistant prostate cancer (mCRPC) patients. Eli Lilly's (Lilly) triple agonist Retatrutide showed positive top-line data in TRIUMPH-1 Phase III trial, with 12mg dose group average weight loss of 28.3% at 80 weeks, nearly half of patients losing over 30%. Merck co-developed TROP2 ADC drug Sac-TMT with Sichuan Kelun Pharmaceutical significantly improved Overall Survival (OS) and Progression-Free Survival (PFS) compared to chemotherapy in treatment of late-stage or recurrent endometrial cancer. Industry Trends & Company Events: CRO industry M&A activity warmed up in China, with small and medium-sized players continuing to exit, industry concentration expected to rise. WuXi XDC announced plans for public market stock buyback up to $100 million. Sunshine Lake Pharma (Sunshine Lake, Uncovered) completed H-share full circulation, effective May 22. United Labs will announce China Phase II clinical trial data for its GLP-1/GIP/GCG triple agonist UBT251 at June ADA meeting.

Analysis framework

The report adopts a "top-down" industry tracking method, first evaluating sector sentiment and relative performance through weekly market cap changes and price change comparisons (vs Hang Seng Index). Then, via "bottom-up" approach, focusing on key catalyst events, including clinical data release before major medical conferences (ASCO, ADA), regulatory policy changes (medical insurance fund review), and corporate capital operations (buybacks, full circulation). This combined analytical framework of macro market sentiment and micro fundamental events helps investors identify structural opportunities and risks amidst short-term volatility.

Methodology notes

• Industry/Industrial Analysis Framework

  Event-driven Weekly Industry Tracking

  Explaining sector short-term price fluctuations and sentiment changes by tracking major clinical data readouts, regulatory news, and company announcements within a specific time window (e.g., one week). This method is commonly used in high-frequency tracking reports to help investors capture short-term trading opportunities.

• Industry/Industrial Analysis FrameworkIndustry Concentration Analysis

  CRO Industry M&A and Small Player Exit

  The report mentions increased CRO industry M&A activity and small player exit, implying the industry is undergoing consolidation. Top companies may expand market share through M&A, increasing industry concentration, thereby improving long-term competitive landscape.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• Duality Biotherapeutics / BioNTech (BNTX.US)

  Beneficiary: Launched global B7H3 ADC Phase III clinical trial, milestone progress

  Strengths

  Possesses cutting-edge ADC technology platform, deep cooperation with multinational pharma BioNTech

  Risks

  Risk of clinical trial failure

• Sichuan Kelun Pharmaceutical (Code Not Listed)

  Beneficiary: TROP2 ADC significantly improved OS/PFS in endometrial cancer trial

  Strengths

  Cooperation with Merck, excellent clinical data

  Risks

  Commercialization below expectations

• WuXi XDC (WuXi XDC)

  Neutral/Positive: Announced $100 million stock buyback

  Strengths

  Plentiful cash flow, management confidence reflected

  Risks

  Geopolitical risks

• China Chain Pharmacy Sector

  Adversely Affected: Intensified review of medical insurance fund abuse

  Weaknesses

  Compliance costs rising, revenue growth limited

  Risks

  Further policy regulatory risk

Key data

• China Healthcare Sector Weekly Price Change-3.7%Underperformed Hang Seng Index (-1.4%)
• China Healthcare Sector YTD Price Change-6.9%Hang Seng Index was -0.1% during the same period
• Pharmacy Sector Weekly Price Change-7.8%Impacted by review of medical insurance fund abuse
• CDMOs YTD Price Change+9.3%Performance better than market
• Retatrutide 12mg Group 80-week Weight Loss Magnitude28.3%Placebo group was 2.2%
• WuXi XDC Buyback Plan Cap$100 millionPublic market buyback

Impact & implications

The report believes that short-term regulatory pressure (especially regarding medical insurance fund use reviews in pharmacies) will continue to suppress sentiment and valuation of related sectors. However, positive clinical data in the innovative drug field (such as ADC and GLP-1 drugs) provides fundamental support for biotech and pharmaceutical sectors. Consolidation trend in CRO industry may benefit top companies by gaining larger market share and pricing power. Investors should pay attention to more data catalysts brought by upcoming ASCO and ADA meetings, and follow-up progress of industry M&A activities.

Risks

• Medical insurance fund regulation policy further tightened, affecting pharmacy revenue
• Clinical trial results below expectations
• Potential impact of geopolitical factors on CXO industry

What to watch

• More abstract data released at ASCO Conference (May 29 - June 2)
• United Labs UBT251 Phase II data at ADA Conference (June 5 - 8)
• Follow-up progress of China CRO industry M&A transactions